Julien Pottecher
Prof Julien Pottecher is an expert in Critical care at Hôpitaux Universitaires de Strasbourg (France). As of October 2026, ScienceLeadR ranks Julien Pottecher in the top 1% of experts worldwide for Pneumonia, Coronavirus Infections and COVID-19. Julien Pottecher has authored 246 publications, the most recent in 2026, and is an investigator in 63 clinical trials, 10 of them ongoing. SLR score: 1,459 (community average: 125). How the SLR is computed.
LeadR Profile
Critical care
Subspecialties: Anesthesiology - Public Health - Neurology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 246
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 63
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 9
Ongoing Clinical Trials
10 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study Evaluating Multifaceted Support for the Implementation of Recommendations for the Prevention and Management of Anemia in Intensive Care Units NCT07771192 — anemia, hospital mortality, intensive care units | N/A | Not yet recruiting | 2026 |
| ASPIC Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care 2024-513327-16-00 — pneumonia, ventilator-associated, antimicrobial stewardship, pneumonia | Phase 3 | Recruiting | 2022 |
| Efficacy of early Argipressin (arginine vasopressin) in the management of intensive care patients with norepinephrine refractory vasoplegic shock a multicentric randomized double blind placebo controlled superiority trial Vaso R 2024-516639-28-00 — arginine vasopressin, arginine, norepinephrine, therapeutics | Phase 3 | Recruiting | 2026 |
| Efficacy of daily IV administration of dornase alfa for up to 14 days post subarachnoid haemorrhage on functional independence at 6 months a multicentre open label randomised controlled trial of the PROBE type Probe 2023-509627-40-01 — hemorrhage, subarachnoid hemorrhage | Phase 3 | Recruiting | 2025 |
| Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients a Multicenter Double Blind Randomised Controlled Trial NCT07506473 — injections, anticoagulants, enoxaparin, thromboembolism, incidence, heparin, venous thromboembolism, thrombosis, heparin, low-molecular-weight, wounds and injuries, injections, subcutaneous, veins | N/A | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map